Contact Us
Find A Doctor

Non-Proliferative Diabetic RetinopathyTrial

Non-Proliferative Diabetic Retinopathy Trial

Enrollment Status

Open Enrollment


2 year randomized study to evaluate the following treatments for NPDR:

1) prompt focal/grid photocoagulation + deferred anti-VEGF,

2) observation + deferred anti-VEGF, or

3) prompt anti-VEGF. *Anti-VEGF = Eylea


  • BCVA 20/25 or better
  • b) Severe NPDR (evident on clinical examination and on 7-modified field or 4-wide field digital fundus photographs)
  • c) No CI-DME on clinical exam and have normal or below the range OCT central subfield thickness. (Spectralis: 305 μm in women and 320 μm in men)


  • Evidence of vitreous hemorrhage or preretinal hemorrhage, history of prior PRP
  • History of DME or DR treatment with laser or intraocular injections of medication within the prior 12 months. No more than 4 injections

Enrollment in the Study

John Choi: 212-979-4024,


Contact Us

Ronald Gentile, MD, Principal Investigator

Address310 E. 14th StreetNew York, NY 10003

John ChoiTel: 212-979-4024

View all locations